$HUMA News

Humacyte Announces Symvess Acellular Tissue Engineered Vessel-Tyod Now Being Used By Arizona Surgeons

Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1

Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript

Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate

BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte Reports Results From Its V012 Phase 3 Trial Of Bioengineered Blood Vessel At Society For Vascular Surgery's Vascular Annual Meeting

HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4

Why Is Humacyte Stock Falling Thursday?

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses

Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients